A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

Shares of Biogen Inc. BIIB advanced 2.12% to $133.13 Friday, on what proved to be an all-around positive trading session for ...

Cardiovascular disease and mental illness commonly co-occur. Addressing them together can improve both mental health and ...

The club will now focus its energy on delivering an exceptional experience through its flagship event - the Biogen 21km Run, ...

Biogen Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia and more.

The stock's fall snapped a three-day winning streak.

US stocks finished in the red on Thursday as investors turned cautious ahead of the non-farm payrolls report, while shares in ...

Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY ...

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

BOSTON and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical ...

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.